Figure 3
Effect of rosiglitazone pretreatment on mammary tumour histopathology. (A) Breast cancer control group, (B) Mammary tumour after treatment with Rosiglitazone: pronounced cell pleomorphism and a low grade of differentiation are demonstrated by multinucleated giant cells, (C) Cisplatin treated mammary tumour. Note the decreased cell density and higher level of fibrosis as sign of a therapeutic effect, (D) Rosiglitazone pre-treated mammary tumour for five days. Note the glandular structure as indicator for a functional differentiation, (E) Quantitative analysis of histopathological studies in mammary tumour where; Cancer control (a), rosiglitazone treated mammary tumour (b), cisplatin treated mammary tumour (c) and rosiglitazone pretreated mammary tumour (d).